Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · IEX Real-Time Price · USD
1.660
-0.075 (-4.32%)
At close: Jul 19, 2024, 4:00 PM
1.700
+0.040 (2.41%)
Pre-market: Jul 22, 2024, 7:33 AM EDT
PACB Revenue
Pacific Biosciences of California had revenue of $200.43M in the twelve months ending March 31, 2024, with 49.54% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $38.81M. In the year 2023, Pacific Biosciences of California had annual revenue of $200.52M with 56.29% growth.
Revenue (ttm)
$200.43M
Revenue Growth
+49.54%
P/S Ratio
2.26
Revenue / Employee
$251,798
Employees
796
Market Cap
452.11M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 200.52M | 72.22M | 56.29% |
Dec 31, 2022 | 128.30M | -2.21M | -1.69% |
Dec 31, 2021 | 130.51M | 51.62M | 65.43% |
Dec 31, 2020 | 78.89M | -12.00M | -13.20% |
Dec 31, 2019 | 90.89M | 12.27M | 15.60% |
Dec 31, 2018 | 78.63M | -14.84M | -15.88% |
Dec 31, 2017 | 93.47M | 2.75M | 3.04% |
Dec 31, 2016 | 90.71M | -2.07M | -2.23% |
Dec 31, 2015 | 92.78M | 32.19M | 53.12% |
Dec 31, 2014 | 60.59M | 32.41M | 115.02% |
Dec 31, 2013 | 28.18M | 2.20M | 8.46% |
Dec 31, 2012 | 25.98M | -7.88M | -23.27% |
Dec 31, 2011 | 33.86M | 32.19M | 1,922.88% |
Dec 31, 2010 | 1.67M | 1.54M | 1,140.00% |
Dec 31, 2009 | 135.00K | -766.00K | -85.02% |
Dec 31, 2008 | 901.00K | -1.26M | -58.34% |
Dec 31, 2007 | 2.16M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bioventus | 522.74M |
Voyager Therapeutics | 119.04M |
EyePoint Pharmaceuticals | 50.02M |
MaxCyte | 44.05M |
Nano-X Imaging | 10.01M |
Absci | 5.35M |
Altimmune | 410.00K |
PACB News
- 6 days ago - PacBio to Report Second Quarter 2024 Financial Results on August 7, 2024 - GlobeNewsWire
- 5 weeks ago - PacBio and International Research Consortium CoLoRS Announce Release of First-Ever HiFi Long-Read Variant Database - PRNewsWire
- 2 months ago - Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases - PRNewsWire
- 2 months ago - PacBio Announces First Quarter 2024 Financial Results - PRNewsWire
- 3 months ago - PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance - PRNewsWire
- 4 months ago - Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes - PRNewsWire
- 4 months ago - PacBio Grants Equity Incentive Award to New Employee - PRNewsWire
- 4 months ago - Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS) - Benzinga